Biopharmaceutical company DURECT Corporation (NASDAQ: DRRX) has expertise in drug discovery, delivery and development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. The company’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. For more information, visit the company’s website at www.durect.com.
DURECT (DRRX) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option